Southland Equity Partners’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Southland Equity Partners’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$217K	Sell	1,371 -6,365	-82%	-$860K	0.04%	287
2026 Q1	$988K	Buy	+7,736	New	+$966K	0.19%	96

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Southland Equity Partners's XBI Position: Q2 2026 in Review

Southland Equity Partners reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 82% in Q2 2026, selling an estimated $860K and leaving 1,371 shares worth $217K. The position accounts for 0.04% of the portfolio, ranked #287.

Southland Equity Partners first reported a position in XBI in Q1 2026 and has held it in 2 quarters since. The position peaked at $988K in Q1 2026. 932 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Southland Equity Partners held 1,371 shares of State Street SPDR S&P Biotech ETF worth $217K as of Q2 2026.
Southland Equity Partners sold 6,365 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $860K.
State Street SPDR S&P Biotech ETF made up 0.04% of Southland Equity Partners's portfolio in Q2 2026, its #287 holding.
Southland Equity Partners first reported a position in State Street SPDR S&P Biotech ETF in Q1 2026 and has held it in 2 quarters since.
Southland Equity Partners's State Street SPDR S&P Biotech ETF position peaked at $988K in Q1 2026.
932 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Southland Equity Partners's 13F filing for Q2 2026, filed 13 Jul 2026.